Skip to main content
SpringerLink
Log in

Candicidin treatment of prostatism: A prospective double-blind placebo-controlled study

  • Originals
  • Published:
Urological Research Aims and scope Submit manuscript

Summary

The polyene macrolide candicidin was investigated in the treatment of benign prostatic hyperplasia (BPH). Forty-one unselected patients with BPH and prostatism were admitted to a prospective, douple-blind placebo-controlled clinical trial. Patients treated with 270 mg candicidin daily for 6 months had a significant decrease in residual urine and a significant increase in maximum flow rate after correction for differences in corresponding bladder volume. Symptoms improved significantly in both the candicidin and the placebo group but no differences in improvement were found between the two groups. The mechanism of the drug's effect is unknown and positive results are much less pronounced than those obtained with surgery. Candicidin appears valuable in the treatment of BPH patients who are a poor surgical risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aalkjaer V (1970) Antimycotics in hypertrophy of the prostate. Urol Int 25:196–200

    Google Scholar 

  2. Abrams PH (1977) A double-blind trial of the effects of candicidin on patients with benign prostatic hypertrophy. Br J Urol 49:67–71

    Google Scholar 

  3. Bates P, Bradley WE, Glen E, Griffiths D, Melchior H, Rowan D, Sterling A, Zinner N, Hald T (1979) The standardization of terminology of lower urinary tract function. J Urol 121:551–554

    Google Scholar 

  4. Caine M, Perlberg S, Meretyk S (1978) A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 50:551–554

    Google Scholar 

  5. Castro JE, Griffiths HJL, Edwards DE (1971) A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy. Br J Surg 58:485–489

    Google Scholar 

  6. Castro JE, Griffiths HJL, Shackman R (1969) Significance of signs and symptoms in benign prostatic hypertrophy. Br Med J 2:598–601

    Google Scholar 

  7. Choudhury A, Maulik AK (1980) Evaluation of the role of injection therapy for benign prostatic hypertrophy. Br J Urol 52:204–207

    Google Scholar 

  8. Clarke R (1937) The prostate and endocrine therapy: A control series. Br J Urol 9:254–271

    Google Scholar 

  9. Donkervoort T, Sterling A, van Ness J, Donker PJ (1977) A clinical and urodynamic study of tadenan in the treatment of benign prostatic hypertrophy. Eur Urol 3:218–225

    Google Scholar 

  10. Farrar DJ, Pryor JS (1976) The effect of bromocriptine in patients with benign prostatic hypertrophy. Br J Urol 48:73–75

    Google Scholar 

  11. von Garrelts B (1957) Micturition in the normal male. Acta Chir Scand 114:197–210

    Google Scholar 

  12. Geller J, Nelson CG, Albert JD, Pratt C (1979) Effect of megestrol acetate on uroflow rates in patients with benign prostatic hypertrophy: Double-blind study. Urology 14:467–474

    Google Scholar 

  13. Gordon HW, Schaffner CP (1968) The effect of polyene macrolides on the prostate gland and canine prostatic hyperplasia. Proc Natl Acad Sci 60:1201–1208

    Google Scholar 

  14. Jensen SK, Hammen S (1982) Treatment of benign hypertrophy of the prostate with candicidin. Ugeskr Laeg 144:26–27

    Google Scholar 

  15. Keshin JG (1973) Effect of candicidin on the human benign hypertrophied prostate gland. Int Surg 58:116–122

    Google Scholar 

  16. Kljucharev BV, Berman NA, Ivanov NM, Margolin AM, Mikhailets GA (1972) The early results of using levorin in patients with prostatic adenoma. Vop Onkol 18:36–41

    Google Scholar 

  17. Meiraz D, Margolin Y, Lev-Ran A, Lazebnik J (1977) Treatment of benign prostatic hyperplasia with hydroxyprogesterone-caproate. Urology 9:144–148

    Google Scholar 

  18. Meyhoff HH, Ingemann L, Nordling J, Hald T (1981) Accuracy in preoperative estimation of prostatic size. Scand J Urol Nephrol 15:45–51

    Google Scholar 

  19. Orkin LA (1974) Efficacy of candicidin in benign prostatic hypertrophy. Urology 4:80–84

    Google Scholar 

  20. Ronchi F, Margonato A, Ceccardi R, Rigatti P, Rossini BM (1982) Symptomatic treatment of benign prostatic obstruction with nicergoline: A placebo controlled clinical study and urodynamic evaluation. Urol Res 10:131–134

    Google Scholar 

  21. Ryall RL, Marshall VR (1982) Normal peak urinary flow rates obtained from small voided volumes can provide a reliable assessment of bladder function. J Urol 217:484

    Google Scholar 

  22. Schaffner CP, Gordon HW (1968) The hypocholesterolemic activity of orally administered polyene macrolides. Proc Natl Acad Sci 61:36–41

    Google Scholar 

  23. Scott FB, Cardus D, Quesada EM, Riles T (1967) Uroflowmetry before and after prostatectomy. South Med J 60:948–952

    Google Scholar 

  24. Scott WW, Wade JC (1969) Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate. J Urol 101: 81–85

    Google Scholar 

  25. Shoukry I, Susset JG, Elhilali MM, Dutartre D (1975) Role of uroflowmetry in the assessment of lower urinary tract obstruction in adult males. Br J Urol 47:559–566

    Google Scholar 

  26. Siroky MB, Olsson CA, Krane RJ: The flow rate nomogram: I. Development. J Urol 122:665–668

  27. Sporer A, Cohen S, Kamat MH, Seebode JJ (1975) Candicidin: Physiologic effect on prostate. Urology 6:298–304

    Google Scholar 

  28. Wang GM, Schaffner CP (1976) Effect of candicidin and colestipol on the testes and prostate glands of Bio 87.20 hamsters. Invest Urol 14:66–71

    Google Scholar 

  29. Wolf H, Madsen PO (1968) Treatment of benign prostatic hypertrophy with progestational agents: A preliminary report. J Urol 99:780–785

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of Wisconsin School of Medicine, Madison, Wisconsin, USA

    K. M.-E. Jensen & P. O. Madsen

  2. Urology Section, Wm. S. Middleton Memorial VA Hospital, 2500 Overlook Terrace, 53705, Madison, WI, USA

    K. M.-E. Jensen & P. O. Madsen

Authors
  1. K. M.-E. Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. O. Madsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jensen, K.ME., Madsen, P.O. Candicidin treatment of prostatism: A prospective double-blind placebo-controlled study. Urol. Res. 11, 7–10 (1983). https://doi.org/10.1007/BF00272701

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00272701

Key words

Search

Navigation